Your browser doesn't support javascript.
Development of a SARS-CoV-2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients.
Wang, Huihui; Li, Xuemei; Li, Tao; Wang, Lianzi; Wang, Li; Lin, Jiawang; Zhang, Shubing; Xu, Yuanhong; Wei, Wei.
  • Wang H; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Li X; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Li T; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Wang L; Institute of Clinical Pharmacology, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Anhui Anti-inflammatory and Immune Medicine Innovation Team, Anhui Medical University, Hefei, China.
  • Wang L; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Lin J; Biohit Healthcare (Hefei) Co., Ltd, Hefei, China.
  • Zhang S; Biohit Healthcare (Hefei) Co., Ltd, Hefei, China.
  • Xu Y; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Wei W; Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Clin Respir J ; 15(5): 499-505, 2021 May.
Article in English | MEDLINE | ID: covidwho-1066647
ABSTRACT

INTRODUCTION:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly to 185 regions and countries around the world with more than 2.8 million confirmed infections and 203,044 deaths. Respiratory diseases caused by SARS-CoV-2 are serious threats to human health.

OBJECTIVES:

To develop a rapid detection kit for new coronavirus antibodies and use it to study the dynamic changes in antibodies in clinically confirmed SARS-CoV-2-infected patients.

METHODS:

The SARS-CoV-2 IgM/IgG antibody test kit (colloidal gold method) was developed. Serum SARS-CoV-2 IgM and IgG antibodies were tested in SARS-CoV-2- and non-SARS-CoV-2-infected persons, respectively. RESULTS AND

CONCLUSION:

The sensitivities of the SARS-CoV-2 IgM/IgG antibody test kit (colloidal gold method) were 50%, 70%, 92.5% and 97.5% after 1-3 days, 4-6 days, 7-9 days and >9 days of admission, respectively, and the specificities of the IgM, IgG and IgM + IgG antibodies were all 100%. Using the SARS-CoV-2 IgM/IgG antibody test kit (colloidal gold method), the positive rates of SARS-CoV-2 IgM and IgG antibodies increased from 50% to 92.5% after 1-3 days, 4-6 days and 7-9 days of admission, which showed an increasing trend. The titers of the SARS-CoV-2 IgM and IgG antibodies in the positive specimens increased with the length of admission.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: Clin Respir J Year: 2021 Document Type: Article Affiliation country: Crj.13331

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: Clin Respir J Year: 2021 Document Type: Article Affiliation country: Crj.13331